Preclinical: CD-001, a dual immunotherapy for solid tumors

[Maxone73]

CD-001 is an innovative immunotherapy combining PD-1 checkpoint blockade with targeted delivery of the cytokine IL-21 to activate tumor-fighting T cells.

Preclinical studies show it enhances immune responses and tumor control more effectively than current PD-1 inhibitors, with a favorable safety profile. Although not yet tested specifically in prostate cancer, its mechanism addresses key challenges in treating advanced prostate tumors.

A phase 1 trial is planned to begin in 2025.

prostatewarriors.com/2025/0...